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Abstract 
 
Objectives: We sought to determine the impact of aortic root calcium on the risk of significant paravalvular 
regurgitation (sPAR) in transcatheter aortic valve replacement (TAVR). 
 
Methods: In 302 consecutive patients from 3 centers, aortic root calcium was quantified volumetrically on 
pre-TAVR multidetector computed tomography (MDCT) in three regions: 1) the aortic valve region, 2) the 
overall left ventricular outflow tract (LVOT) and 3) the upper LVOT. Transcathether heart valve (THV) 
oversizing was calculated as (THV nominal area/MDCT annular area−1)°—100. The study endpoint sPAR 
was a composite of post-dilatation (PD) and PAR > mild. 
 
Results: sPAR occurred in 15% (46/302) of patients. Upper LVOT calcium volume was more predictive of 
sPAR than overall LVOT calcium volume, with an area under the receiver operating curve (AUC) (95% 
confidence interval [CI]) of 0.80 (0.67–0.89) vs. 0.60 (0.51–0.70); p=0.0001. The optimal cut-off calcium 
volume thresholds determined from receiver operating curves were 21mm3 and 30mm3 for upper LVOT 
and overall LVOT calcium, respectively. Upper LVOT calcium ≥ 21mm3, but not overall LVOT calcium ≥ 
30mm3, independently predicted sPAR, odds ratio (95%CI): 9.5 (4.1–22.3) vs 1.6 (0.6–2.7). Upper LVOT 
calcium was more predictive of sPAR in patients with THV oversizing ≥ 13% compared to patients with THV 
oversizing<13%, AUC (95% CI): 0.83 (0.72–0.93) vs. 0.67 (0.51–0.74); p < 0.0001. 
 
Conclusions: Upper LVOT calcium predicts more-than-mild paravalvular regurgitation following TAVR or the 
need for postdilatation. Upper LVOT calcium is most predictive of paravalvular regurgitation in the event of 
THV oversizing ≥ 13%. 
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1. Introduction 
 
Post-procedural paravalvular regurgitation (PAR) remains a significant limitation in transcatheter aortic valve 
replacement (TAVR) and is associated with increased mortality.1 Potential future broadening of TAVR 
indications to lower-risk patients calls for further improvement in procedural outcomes. Appropriate 
transcatheter heart valve (THV) sizing relative to the aortic annulus is crucial to secure anchoring and 
prevent PAR without increasing the risk of aortic root injury.1–4 Contrast-enhanced multidetector CT 
(MDCT) has emerged to play a key role in TAVR planning.5 Indeed, introduction of an MDCT-based THV 
sizing algorithm has been shown to reduce the risk of PAR.6 In addition to the assessment of annular 
dimensions, MDCT allows for detailed assessment of aortic root and left ventricular outflow tract calcium 
(LVOT) calcification. Through detailed quantitative calcium analysis it has recently been demonstrated that 
the distribution and amount of calcium in the aortic root and LVOT have implications for the risk of aortic root 
injury.3 Moreover, calcium may prevent apposition of the THV device to the aortic wall, thus creating a nidus 
for PAR.7,8 The majority of previous studies addressing the implications of MDCT-based calcium evaluation 
for PAR have been limited by single-center design, small cohort size and lack of standardized methodology 
for calcium quantification.7–16 In addition, the interplay between aortic root calcium and THV sizing for 
the risk of PAR is not fully understood. Thus, the objective of this multicenter study was to determine the 
implication of calcium volume and distribution for PAR > mild and need for post-dilatation using a novel 
calcium quantification methodology. 
 
 
2. Methods 
 
2.1. Study population and TAVR procedure 
324 consecutive patients who underwent pre-TAVR MDCT and TAVR at 3 institutions (Aarhus University 
Hospital, Aarhus, Denmark, n=187; St Paul's Hospital, Vancouver, Canada, n=69 and London Chest 
Hospital, London, UK, n=68) between August 2011 and February 2014 were evaluated for inclusion in this 
observational study. TAVR was performed with the balloon-expandable Sapien XT transcatheter heart valve 
(THV; Edwards Lifesciences, Irvine, CA) according to standard practice.17–19 THV size selection was 
based on MDCT analysis performed at each participating center.20 Immediately after THV deployment PAR 
was evaluated by TEE and/or angiography. Postdilatation was performed in the event of PAR > mild using 
the same balloon volume as for THV implantation or with an additional 1–2 cc at the discretion of the 
treating physician. 
 
2.2. CT image acquisition 
As part of routine clinical practice, all patients underwent contrast enhanced MDCT scans in the 
craniocaudal direction with retrospective ECG-gating. MDCT protocols were applied according to each 
centers' standard practice. Scans were performed on either a 64-slice Discovery HD 750 high-definition 
scanner (GE Healthcare, Milwaukee, WI) with a scanner detector collimation width of 0.625 mm, detector 
coverage of 40 mm, gantry rotation time of 0.35 s, and scan pitch of 0.16–0.20 (adjusted per heart rate), or 
a Siemens Somatom Definition Flash Dual-Source scanner (Siemens Healthcare, Erlangen, Germany) with 
a 128°—0.625mm collimation, z-flying spot, gantry rotation time of 0.28 s, and scan pitch of 0.20–0.40 
(depending on heart rate).21  
 
2.3. MDCT image analysis 
For the purpose of this study, all images were transferred to a core lab (Aarhus University Hospital, 
Denmark) after the TAVR procedure and post-processed offline using dedicated TAVR planning software 
(3mensio Structural Heart, 3mensio Medical Imaging BV, Bilthoven, the Netherlands).3 All analyses was 
performed by one experienced TAVR MDCT reader in a blinded fashion without knowledge regarding 
patient characteristics, the TAVR procedure, echocardiographic data or clinical outcomes. Aortic root 
dimensions were determined as outlined in the supplementary data. As previously described,3 calcium was 
quantified using patientspecific detection threshold in three specific regions (Fig. 1): 1. The overall LVOT 
(from the aortic annulus plane and 10mm into the left ventricle), 2. The upper LVOT (from the aortic annulus 
plane and 2mm into the left ventricle) and 3. The aortic valve region (from the aortic annulus plane to the left 
coronary ostia) (see also supplementary data). The distal boundary of the upper LVOT region (ie, 2mm into 
the left ventricle) was chosen based on previously reported distances from the lower rim of the THV to the 
aortic annulus in order to include the calcium that would be in direct contact with the THV device.22,23 In 
patients with calcium in the upper LVOT, the protrusion of annular calcium nodules into the lumen was 
evaluated. The severity of calcium lumen protrusion was assessed by relating the calcium nodule long-axis 
dimension to the corresponding annulus diameter (Fig. 1). 
 
2.4. Echocardiographic assessment 
All pre-discharge TTEs were retrospectively reviewed by 1 of 2 cardiologists with>4 years experience in 
post-TAVR echocardiography blinded to THV size, pre-TAVR echocardiographic and MDCT data. PAR was 
graded as mild, moderate or severe according to the Valve Academic Research Consortium-2 criteria.24 
THV function was assessed by determining the mean trans-THV gradient and effective orifice area (EOA). 
 
2.5. Study endpoints 
The study endpoint was a composite of postdilatation (as a surrogate of procedural PAR > mild) and/or PAR 
> mild at discharge. This composite endpoint is designated “significant PAR” (sPAR). Data on survival and 
all-cause mortality were collected from dedicated TAVR registries and patient records. 
 
2.6. Statistical analysis  
Continuous parametric variables are presented as mean ± SD and compared using the Students t-test. 
Continuous nonparametric variables are presented as median [interquartile range] and compared using 
the Mann-Whitney-U test. Categorical variables are presented as frequencies (percentages) and compared 
using Fisher's exact test or chisquare as appropriate. Non-parametric receiver operating curve (ROC) 
analysis was performed in order to test the discriminatory power of calcium volumes stratified by region, 
annular calcium protrusion and THV oversizing for prediction of the combined endpoint, sPAR. Area 
under the curves (AUCs) were compared using the method of DeLong et al.25 The optimal cut-off points 
maximizing the sum of sensitivity and specificity were derived from the ROC curves. Multivariable logistic 
regression analysis was performed to determine the predictive value for sPAR of an upper LVOT/overall 
LVOT calcium volume, as well as annular calcium protrusion, above the optimal cut-off point. Adjusting 
was performed for the optimal degree of THV sizing for prediction of sPAR (< 13%), as well as STS 
predicted risk of mortality and access route (as a 3-grouped categorical variable) that both trended to differ 
significantly between the control and the sPAR groups. The impact of calcium volume in the upper quartile 
and PAR > mild at discharge on all-cause mortality were evaluated using a Cox proportional hazards 
model adjusted for variables potentially influencing mortality (age, sex, STS predicted risk of mortality and 
AVA at discharge). Log-rank test was performed to compare survival distributions. A two-tailed p 
value < 0.05 was considered statistically significant. All statistical analyses were performed using Stata 12 
(StataCorp LP, College Station,Texas). 
 
 
3. Results 
 
3.1. Study population 
Of the 324 patients evaluated for study inclusion, 22 patients where excluded. The MDCT quality was 
inadequate for calcium quantification in 10 patients (1 of these patients would have meet the composite 
endpoint of sPAR). THV function/degree of PAR could not be accurately determined from the available TTE 
in 10 patients (none of these patients underwent postdilatation), and 2 patients died (1 from coronary 
obstruction during the procedure, and 1 from cardiogenic shock immediately post-procedural) before pre-
discharge TTE was performed. Thus, the final study cohort comprised 302 patients. A total of 46 (15%) 
patients reached the composite endpoint sPAR. Baseline clinical, echocardiographic, and MDCT  
characteristics of the study population are presented in Tables 1 and 1S (supplementary data). Median age 
was 83 years, 50% were female, and median STS predicted risk of mortality was 5.5%. There were no 
significant differences between the control and sPAR groups in any of the baseline characteristics. 
 
3.2. Procedural data, in-hospital complications and pre-discharge echocardiographic data 
Procedural data and pre-discharge echocardiographic data are depicted in Table 2 while frequencies of in-
hospital complications are depicted 2S (supplementary data). Mean ± SD (range) nominal THV oversizing 
relative to MDCT annular area was 17 ± 14% (−23 to 44%). Postdilatation was performed in 7% (21/302) of 
the patients and PAR > mild at discharge was present in 10% (30/302) of the patients. Mean THV oversizing 
was lower in the sPAR group compared to the control group, 13 ± 13% vs. 18 ± 14%, p=0.04. In the sPAR 
group, 57% had moderate PAR and 9% severe PAR at discharge. In 5 of 21 (24%) patients, postdilatation 
did not reduce PAR to≤mild at the predischarge echocardiography. In 2 of these patients the THV implanted 
was undersized relative to the annulus area, whereas the other 3 patients had upper LVOT calcium volumes 
in the upper quartile. Median upper LVOT calcium volume was 36 (11–82) mm3 in the 5 patients where 
postdilatation did not reduce PAR to≤mild vs. 13 (0–73) mm3 in the 16 patients where PAR was reduced 
to≤mild. Pre-discharge AVA was higher in the control group as compared to the sPAR group (Table 2). 
 
3.3. Calcium analysis 
Individual patient calcium volumes in relation to the anatomic region are shown in Fig. 2, and summarized in 
Table 3. There were no differences in the median contrast attenuation or the median calcium detection 
threshold between groups. sPAR patients had significantly more upper LVOT and overall LVOT calcium 
compared to patients in the control group. In contrast, aortic valve region calcium volume did not differ 
between groups. In ROC analysis, upper LVOT calcium volume had significantly higher discriminatory value 
regarding sPAR as compared to the overall LVOT calcium volume (Table 4). Aortic valve region calcium 
volume did not predict sPAR. If patients who underwent postdilatation were excluded from the analysis, the 
results were similar (Table 4S). THV oversizing predicted sPAR, AUC (95%CI) 0.75 (0.63–0.84), with an 
optimal cut-off point at 13%. In 22 sPAR patients with THV oversizing ≥ 13%, median (IQR) upper LVOT 
calcium volume was higher than in 24 sPAR patients less than 13% THV oversizing, 63 (30–75) vs. 0 (0–11) 
mm3; p < 0.0001. Overall, upper LVOT calcium volume was significantly more predictive of sPAR in 205 
patients with THV oversizing ≥ 13% compared to 97 patients with THV oversizing<13%, AUC (95% CI): 0.83 
(0.72–0.93) vs. 0.67 (0.51–0.74); p < 0.0001. Excluding 3 patients with THV undersizing from the 97 
patients with THV oversizing<13% did not affect the predictive value of upper LVOT calcium volume for 
sPAR, AUC (95% CI): 0.67 (0.51–0.74) vs. 0.69 (0.53–0.77). The degree of annular calcium nodule 
protusion into the lumen predicted sPAR, AUC (95%): 0.72 (0.60–0.80). Of the 95 (31%) patients 
with calcium in the upper LVOT, 22 had one or more calcium nodules protruding ≥ 25% into the lumen. The 
combined endpoint of sPAR occurred in 19 of these 22 (86%) patients. 
 
3.4. Multivariable analysis of predictors of sPAR 
Results of multivariable logistic regression analysis for prediction of sPAR are shown in Table 5. Upper 
LVOT calcium volume ≥ 21mm3 and annular calcium protrusion ≥ 25%, but not overall LVOT ≥30mm3 
calcium, independently predicted sPAR when adjusting for THV oversizing<13%, STS predicted risk of 
mortality, and access route. 
 
3.5. Impact of calcium volume and PAR > mild at discharge on mortality Median (IQR) follow-up time with 
regard to survival status after TAVR was 1.4 (1.0–2.0) years ranging from 3 days to 3.8 years. During 
follow-up, 59 (20%) patients died. When adjusted for age, sex, STS predicted risk of mortality and AVA at 
discharge, neither upper LVOT calcium volume (HRadjusted, 0.8 (95% CI, 0.3–2.1); p=0.53) nor total 
aortic root calcium volume (HRadjusted, 1.2 (95% CI, 0.6–2.3); p=0.32) in the upper quartile was associated 
with mortality. PAR > mild was associated with increased all-cause mortality during the follow-up period, 
HRadjusted: 2.2 (95% CI, 1.2–4.7), p=0.02 (Fig. 3). Twelve-month mortality in the 5 patients in whom 
postdilatation did not reduce PAR to≤mild was 40% vs. 13% in the 16 patients with PAR reduced to≤mild. 
 
 
4. Discussion 
 
This study demonstrates an association between aortic root calcium and the risk of significant PAR (ie. PAR 
> mild and/or the need of postdilatation) in TAVR. Specifically, the calcium volume in the upper LVOT 
predicts sPAR better than overall LVOT calcification, while aortic valve region calcium does not influence 
the risk of sPAR. PAR > mild at discharge, but not the calcium volume per se, were associated with 
increased all-cause mortality in our cohort. In line with data from Khalique et al.8 our study shows that upper 
LVOT calcium, but not overall LVOT calcium, predicts sPAR independent of THV sizing. However, upper 
LVOT calcium volume was significantly more predictive of sPAR in patients with THV oversizing 
≥ 13% (the optimal cut off point for prediction of sPAR by THV sizing) compared to patients with THV 
oversizing<13%. The inverse relation between THV oversizing and PAR is well established, and generally 
5–20% oversizing of the Sapien XT THV has been advised (taking into account the limited THV sizes 
available).1,4,6,20 Thus our results probably reflects the fact that in patients with THV oversizing<13%, the 
presence of PAR to a greater extent was explained by inadequate oversizing rather that upper LVOT 
calcium. Importantly, this may have been a conscious choice as a larger valve size may have resulted in 
more severe annular oversizing which, in the setting of nodular calcification, may be associated with aortic 
root injury.2,3 As THV size selection continues to improve through growing use of 3-dimensional imaging 
modalities and specific THV sizing guidelines, the contribution of inappropriate sizing to PAR most likely will 
decline.4,6,20,26 Therefore, to continuously reduce the incidence of PAR, appropriate consideration of 
other contributing factors, such as calcium volume and distribution, remains crucial. Prospectively evaluated 
guidelines for sizing of the Edwards Sapien XT recommend a lower range of oversizing in the event 
of more than minimal LVOT calcification.6 Further larger prospective studies are warranted to validate our 
results and to further specify the optimal degree of THV sizing in relation to calcium volume and distribution 
to balance the risk of PAR and aortic root injury. Data from randomized trials and registries show that PAR > 
mild is associated with a worse clinical outcome, including mortality.1 Even mild PAR has been reported to 
be a predictor of mortality, albeit data are conflicting and therefore PAR > mild was chosen as endpoint in 
the present study.27 Studies addressing the impact of calcium distribution on the risk of PAR have been 
limited in their ability to study clinical outcomes, largely due to limited cohort sizes. In contrast, our 
study confirmed the clinical significance of more than mild PAR at discharge with a 2-fold increase in 12-
month all-cause mortality. In previous studies on aortic root calcification and pre-TAVR MDCT, there was 
large variation in the applied methodologies, thus direct comparisons between studies are not possible.7–16 
The varied methodology reflects the fact that aortic root and LVOT calcium assessment on contrast-
enhanced pre-TAVR MDCT scans is challenging. Firstly, the complex anatomic nature of the aortic root 
makes it challenging to accurately perform 3-dimensional regional calcium quantification in a consistent 
fashion. In addition, contrast enhancement is essential in order to obtain detailed anatomical information 
regarding the aortic root and annulus. Consequently, using a threshold-based calcium quantification 
strategy is problematic since a fixed calcium detection threshold does not take into account the variability in 
contrast attenuation caused by issues related to e.g. acquisition- and patient characteristics. Most previous 
studies have applied various empiric fixed calcium-detection thresholds ranging from 500 to 850HU.10–12 
When applying a specific calcium quantification methodology across different scanners/acquisition protocols, 
a patient-specific calcium detection threshold adjusting for variation in contrast attenuation may be 
more appropriate. Recent data from Jilaihawi et al.9 emphasize that the ability of aortic root calcium to 
predict PAR is dependent on the calcium detection threshold used, however even in that study a fixed 
threshold was used with no adjustment for the variation in contrast attenuation between individual MDCT 
scans. In order to comply with these issues, the present study used dedicated software that ensures 
perpendicular views along a centerline and provides 3-dimensional VOI definition capabilities allowing for 
granular regional calcium quantification in the aortic root and LVOT. Moreover, the present study 
incorporates patient-specific calcium detection thresholds to adjust for variability of mean contrast 
attenuation in the aortic lumen. The AUC value of 0.80 for discrimination of sPAR by upper LVOT calcium 
volume as found in the present study is in the upper range of AUC-values for calcium measures reported in 
other studies using different methodologies. 7–10,13,16 Our multicenter design with inclusion of MDCT 
examinations acquired with three different scanners and protocols increases the external validity of our 
calcium quantification method and our findings in general potentially making them more applicable to 
real-world clinical practice across different scanners and acquisition protocols. Finally, as opposed to 
previous studies, we evaluated the significance of protrusion of calcium nodules into the lumen at the 
annular level. Calcium nodular protrusion did significantly predict sPAR and there was a high rate (86%) of 
sPAR in patients with annular calcium nodule protrusion ≥ 25%. Although not as predictive as upper LVOT 
calcium volume, this simple metric is readily available during standard pre-TAVR MDCT planning. 
Reduction of PAR severity by procedural postdilatation has been proven feasible, however the use of 
postdilatation varies significantly between institutions.28–30 We reported use of postdilatation in 7% of 
patients, which is in the lower range of what has been reported in previous studies. This may partly be 
explained by increased operator experience and more appropriate THV sizing through the use 3-
dimensional imaging compared to studies performed earlier in the TAVR era.29,30 Similar to a recent study 
by Watanabe et al.,28 we found that in approximately 24% of cases where postdilatation was performed, it 
did not reduce PAR to≤mild. The sample size in the current study does not allow for identification of specific 
predictors of non-response to postdilatation, but contributing factors may include high levels of calcium, 
malpositioning or excessive THV undersizing.30 Of note, postdilatation is not without risks and has been 
reported to constitute an elevated risk for aortic root injury and possibly stroke.3,29,30 The higher incidence 
of THV embolization in the sPAR group in this study was likely due to a combination of the use of 
postdilatation, lower degree of oversizing and higher prevalence of heavy, bulky calcifications potentially 
increasing the risk of THV displacement during balloon inflation.31 Consequently, when considering whether 
or not to perform postdilatation during the procedure detailed information as provided by pre-TAVR MDCT 
may be of significant value. This study concerns the Edwards Sapien XT THV, but recently the newer 
generation Edwards Sapien 3 has emerged. The Sapien 3 valve, through the introduction of a sealing cuff 
and facilitated accurate positioning, has demonstrated lower rates of moderate/severe PAR compared 
to previous generations.32 However, the incidence moderate/severe PAR is still around 3.5%, and with the 
well-established impact of PAR on mortality and the introduction of TAVR in younger and lower risk patients, 
uncovering factors associated with PAR remains important. 33,34 While the threshold of oversizing may be 
different with the Sapien 3 THV, there are no engineering explanations as to why calcium would not have 
similar relative impact on the risk of PAR. 
 
 
5. Limitations 
This study has the inherent limitations of an observational design. Furthermore, postdilatation was 
performed at the discretion of the treating operator based on intra-procedural TEE and/or angiography. 
Hence, there is no data confirming the actual severity of PAR before postdilatation. Grading of PAR can be 
challenging. However, all TTEs were analyzed by echo-cardiographers experienced in post-TAVR imaging 
and graded according to the VARC-2 criteria.24 TEE may allow more accurate evaluation of PAR, but in the 
vast majority of centers, standard clinical post-TAVR follow-up imaging consists of TTE and therefore this 
modality was used in the current study. Importantly, patients were excluded if TTE quality did allow 
assessment of PAR severity. Several factors that were not assessed in the present study, including 
implantation depth, co-axiality relative to the orientation of the aortic root/LVOT and THV device type may 
play a role in causing PAR. 
 
 
6. Conclusion 
Upper, in contrast to overall, LVOT calcium, independently predicts PAR > mild and need for postdilatation. 
Moreover, upper LVOT calcium is more predictive of PAR > mild and the need for postdilatation in more 
oversized than less oversized THVs. Importantly, aortic valve region calcium does not appear to play any 
role in predicting PAR > mild and the need for postdilatation. Future prospective studies are warranted to 
elucidate whether THV size selection can be refined by quantitative assessment of calcium distribution in 
order to reduce PAR.  
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